Links

Last minute


Ark Readies Phase 2 Study
Drug Discovery & Development
Ark Therapeutics Group plc has completed the dose ranging Phase 1 section of the academic study of Ark's VEGF-D adenoviral vector treatment for refractory angina. The study is being carried out in collaboration with the AIV Institute in Finland.
Ark Therapeutics Group plc Interim Management StatementPharmaLive.com (press release)

all 3 news articles »

Medtronic's Resolute DES nets broader indications in EU
Cardiovascular Business
The Resolute Integrity DES is now indicated in countries outside the US that accept the CE Mark for the following patient and lesion types: acute coronary syndromes, acute MI, unstable angina, diabetes mellitus, bifurcations, multi-vessel disease, ...
Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in EuropeMarketWatch (press release)

all 2 news articles »

MedPage Today

Post-PCI Bleeds Drop with Shifts in Drug Strategy
MedPage Today
According to previous research, among patients with elective PCI, unstable angina/non-ST-segment elevation myocardial infarction (NSTEMI), and STEMI, there was a "a modest but significant decrease" in post-PCI bleeding from 2005 to 2009 (2.49% to ...

 

Interesting pages

angina ludwig



Bookmark us
  • Bookmark this page on StumbleUpon
  • Bookmark this page on del.icio.us
  • Bookmark this page on Digg
  • Bookmark this page on DZone
  • Bookmark this page on MisterWong
  • Bookmark this page on Netvouz
  • Bookmark this page on ThisNext
  • Bookmark this page on Wists